Full text is available at the source.
Abstract
CagriSema, a combination of cagrilintide and semaglutide, may improve glycaemic control and body weight in Type 2 diabetes.
- The efficacy of CagriSema may vary based on dosage and comparison with other treatments.
- Improvements in glycaemic control and body weight are associated with the use of this combination therapy.
- Safety evaluations are part of the assessment of CagriSema's use in managing Type 2 diabetes.
Simplified